It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The wake-active orexin system plays a central role in the dynamic regulation of glucose homeostasis. Here we show orexin receptor type 1 and 2 are predominantly expressed in dorsal raphe nucleus-dorsal and -ventral, respectively. Serotonergic neurons in ventral median raphe nucleus and raphe pallidus selectively express orexin receptor type 1. Inactivation of orexin receptor type 1 in serotonin transporter-expressing cells of mice reduced insulin sensitivity in diet-induced obesity, mainly by decreasing glucose utilization in brown adipose tissue and skeletal muscle. Selective inactivation of orexin receptor type 2 improved glucose tolerance and insulin sensitivity in obese mice, mainly through a decrease in hepatic gluconeogenesis. Optogenetic activation of orexin neurons in lateral hypothalamus or orexinergic fibers innervating raphe pallidus impaired or improved glucose tolerance, respectively. Collectively, the present study assigns orexin signaling in serotonergic neurons critical, yet differential orexin receptor type 1- and 2-dependent functions in the regulation of systemic glucose homeostasis.
The wake-active orexin system plays a central role in the dynamic regulation of glucose homeostasis. Here the authors report that inactivation of the orexin receptor type 1 or 2 in serotonergic neurons differentially regulate systemic glucose homeostasis in the context of diet induced obesity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Max Planck Institute for Metabolism Research, Department of Neuronal Control of Metabolism, Cologne, Germany (GRID:grid.418034.a) (ISNI:0000 0004 4911 0702); University Hospital Cologne, Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), Cologne, Germany (GRID:grid.411097.a) (ISNI:0000 0000 8852 305X); University of Cologne, Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (CECAD) and Center for Molecular Medicine Cologne (CMMC), Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777)
2 University of Cologne, Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (CECAD) and Center for Molecular Medicine Cologne (CMMC), Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777); University of Cologne, Biocenter, Institute for Zoology, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777)
3 Max Planck Institute for Metabolism Research, Department of Neuronal Control of Metabolism, Cologne, Germany (GRID:grid.418034.a) (ISNI:0000 0004 4911 0702); University Hospital Cologne, Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), Cologne, Germany (GRID:grid.411097.a) (ISNI:0000 0000 8852 305X); University of Cologne, Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (CECAD) and Center for Molecular Medicine Cologne (CMMC), Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777); National Center for Diabetes Research (DZD), Neuherberg, Germany (GRID:grid.6190.e); University of Potsdam, Institute of Nutritional Science, Department of Molecular and Experimental Nutritional Medicine, Nuthetal, Germany (GRID:grid.11348.3f) (ISNI:0000 0001 0942 1117)
4 University of Iowa, Carver College of Medicine, Department of Neuroscience and Pharmacology, Iowa City, USA (GRID:grid.214572.7) (ISNI:0000 0004 1936 8294)
5 Boston Children’s Hospital and Harvard Medical School, Division of Endocrinology, Department of Pediatrics, F.M. Kirby Neurobiology Center, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Beth Israel Deaconess Medical Center and Harvard Medical School, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547)
6 Beth Israel Deaconess Medical Center and Harvard Medical School, Department of Neurology, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547)
7 Beth Israel Deaconess Medical Center and Harvard Medical School, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547)
8 Max Planck Institute for Metabolism Research, Department of Neuronal Control of Metabolism, Cologne, Germany (GRID:grid.418034.a) (ISNI:0000 0004 4911 0702); University Hospital Cologne, Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), Cologne, Germany (GRID:grid.411097.a) (ISNI:0000 0000 8852 305X); University of Cologne, Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (CECAD) and Center for Molecular Medicine Cologne (CMMC), Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777); National Center for Diabetes Research (DZD), Neuherberg, Germany (GRID:grid.6190.e)